Last $0.33 USD
Change Today +0.024 / 7.74%
Volume 1.3M
HEB On Other Exchanges
As of 8:04 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

hemispherx biopharma inc (HEB) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/14 - $0.55
52 Week Low
11/25/13 - $0.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

hemispherx biopharma inc (HEB) Related Bloomberg News

View More Bloomberg News

hemispherx biopharma inc (HEB) Related Businessweek News

No Related Businessweek News Found

hemispherx biopharma inc (HEB) Details

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company products comprise Ampligen, an experimental drug, which is under clinical development for the treatment of chronic fatigue syndrome, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma. Its products also include Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza, seasonal influenza, and other emerging viruses. The company has a strategic alliance with Bioclones (Pty) Ltd. to develop various projects. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

39 Employees
Last Reported Date: 03/14/14
Founded in 1990

hemispherx biopharma inc (HEB) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.0M
Executive Vice Chairman, Chief Financial Offi...
Total Annual Compensation: $553.8K
Chief Medical Officer and Medical Director
Total Annual Compensation: $265.5K
Compensation as of Fiscal Year 2013.

hemispherx biopharma inc (HEB) Key Developments

Hemispherx BioPharma and Army Medical Research Institute of Infectious Diseases Agree to Test Alferon and Ampligen to Evaluate against the Ebola Virus

Hemispherx BioPharma and the Army Medical Research Institute of Infectious Diseases have agreed to test Alferon, the only commercially approved natural alpha interferon drug in the U.S., and experimental drug Ampligen, to evaluate them against the Ebola virus.

Hemispherx Biopharma Announces Earnings Results for the Six Months Ended June 30, 2014

Hemispherx Biopharma announced earnings results for the six months ended June 30, 2014. The net loss (including non-cash effects) was approximately $8,792,000 or $0.05 per share as compared to a net loss of $7,894,000 or $0.05 per share for the same six month period in 2013.

Hemispherx Biopharma, Inc. to Report Q2, 2014 Results on Aug 08, 2014

Hemispherx Biopharma, Inc. announced that they will report Q2, 2014 results After-Market on Aug 08, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.33 USD +0.024

HEB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $241.81 USD +3.88
AstraZeneca PLC 4,579 GBp +42.00
Baxter International Inc $72.54 USD -0.56
Medigene AG €3.82 EUR -0.086
Sarepta Therapeutics Inc $21.78 USD -0.75
View Industry Companies

Industry Analysis


Industry Average

Valuation HEB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 337.2x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 234.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at